Browse by Audience
Skip to content
Papers of the Week
Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy.
Abstract
Epidermal growth factor receptor (EGFR) mutations have a low incidence in squamous cell lung cancer (SqCLC), and the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in -mutated SqCLC is far less than that in -mutated lung adenocarcinoma. The treatment strategy for patients with mutated non-small cell lung cancer who are refractory to EGFR TKIs has become a current dilemma and challenge.